Ardelyx (ARDX) Current Deferred Revenue (2013 - 2026)
Ardelyx's (ARDX) quarterly Current Deferred Revenue came in at $3.2 million in Q1 2026, down 70.24% YoY from $10.9 million in Q1 2025, and up 169.32% on a QoQ basis from $1.2 million in Q4 2025.
Ardelyx (ARDX) Current Deferred Revenue (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 12 years of Current Deferred Revenue data on file, last reported at $3.2 million in Q1 2026.
- Quarterly Current Deferred Revenue fell 70.24% year-over-year to $3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 million (down 70.24% YoY) and the FY2025 annual result came in at $1.2 million, down 88.71% from the prior year.
- Current Deferred Revenue grew to $3.2 million in Q1 2026, from $1.2 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $10.9 million in Q1 2025 to a low of $1.2 million in Q4 2025.
- A 5-year average of $6.5 million and a median of $6.4 million in 2025 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue jumped 659.58% — and 2025, when it tumbled 88.71%.
- Tracing ARDX's Current Deferred Revenue over 5 years: stood at $4.2 million in 2022, then surged by 70.55% to $7.2 million in 2023, then soared by 48.79% to $10.7 million in 2024, then plunged by 88.71% to $1.2 million in 2025, then surged by 169.32% to $3.2 million in 2026.
- The last three Current Deferred Revenue figures came in at $3.2 million (Q1 2026), $1.2 million (Q4 2025), and $6.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.74 Mn |
| Mar 31, 2026 | 3.25 Mn |
| Dec 31, 2025 | 1.21 Mn |
| Sep 30, 2025 | 6.58 Mn |
| Jun 30, 2025 | 6.28 Mn |
| Mar 31, 2025 | 10.91 Mn |
| Dec 31, 2024 | 10.69 Mn |
| Sep 30, 2024 | 7.27 Mn |
| Jun 30, 2024 | 10.83 Mn |
| Mar 31, 2024 | 6.59 Mn |
| Dec 31, 2023 | 7.18 Mn |
| Sep 30, 2023 | 4.07 Mn |
| Jun 30, 2023 | 5.96 Mn |
| Mar 31, 2023 | 5.55 Mn |
| Dec 31, 2022 | 4.21 Mn |
| Sep 30, 2022 | 4.00 Mn |
| Jun 30, 2022 | 10.00 Mn |
| Sep 30, 2021 | 527,000.00 |
| Jun 30, 2021 | 1.41 Mn |
| Mar 31, 2021 | 2.72 Mn |